Currency In USD
| Previous Close | 5.94 |
| Open | 6.14 |
| Day High | 6.14 |
| Day Low | 5.73 |
| 52-Week High | 20.11 |
| 52-Week Low | 5.62 |
| Volume | 40,868 |
| Average Volume | 17,557 |
| Market Cap | 39.13M |
| PE | -1.29 |
| EPS | -4.47 |
| Moving Average 50 Days | 7.16 |
| Moving Average 200 Days | 7.75 |
| Change | -0.17 |
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
GlobeNewswire Inc.
Jul 31, 2025 10:00 AM GMT
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line N